Bristol-Myers Squibb and Ono Enter into Strategic Agreement

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA® (abatacept) in Japan.

BMS-936558/ONO-4538, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono and Medarex, Inc. When Bristol-Myers Squibb acquired Medarex in 2009, it also acquired Medarex's rights to develop and commercialize the anti-PD-1 antibody in North America. Under the terms of the agreement announced today, Ono will grant Bristol-Myers Squibb exclusive rights to develop and commercialize BMS-936558/ONO-4538 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize BMS-936558/ONO-4538.

Also under the agreement, the companies will co-develop and co-commercialize ORENCIA, a biologic therapy for rheumatoid arthritis, in Japan. The agreement applies to both the currently approved intravenous (IV) formulation of ORENCIA and the subcutaneous (SC) formulation of ORENCIA, and includes all current and future indications. ORENCIA IV was launched in Japan in September 2010 by Bristol-Myers Squibb's Japanese subsidiary, Bristol-Myers K.K., and is indicated for use in patients for whom other therapies have failed. ORENCIA SC is currently in Phase III development in Japan. Bristol-Myers K.K. will distribute and book sales of ORENCIA IV. Ono will distribute and book the sales of ORENCIA SC. The companies will jointly promote both formulations with Ono's participation beginning when the post-marketing surveillance period for ORENCIA IV has concluded, which is expected to be in 2013.

"Bristol-Myers Squibb is pleased to enter into this important collaboration with Ono Pharmaceutical that further enhances our position as a leader in immuno-oncology," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "Obtaining expanded rights to this anti-PD-1 antibody through our String of Pearls strategy will enable broader global development of this promising cancer immunotherapy as we continue to build our pipeline and understanding in this exciting area."

"In addition we are very pleased to be able to continue the important work of bringing ORENCIA to patients in Japan with Ono, a highly-respected Japanese company. We believe that our collective resources will benefit the rheumatoid arthritis patients we serve."

"We are delighted to further strengthen the relationship already established between Ono and Bristol-Myers Squibb. BMS-936558/ONO-4538 represents a promising investigational agent in the emerging field of immuno-oncology. Together with Bristol-Myers Squibb we will be better able to quickly bring this potential new medicine to patients in need worldwide," said Gyo Sagara, president, representative director and CEO of Ono Pharmaceutical.

"ORENCIA has an innovative mechanism of action to suppress the inflammation pathway in rheumatoid arthritis. We are also very delighted to collaborate with Bristol-Myers Squibb on such an important product. Adding ORENCIA will expand our product portfolio in orthopedics, one of our strategic therapeutic areas."

About BMS-936558/ONO-4538
BMS-936558/ONO-4538 is a fully human antibody directed against PD-1 (Programmed cell death 1). PD-1 is expressed on the surface of activated T cells and is involved in the negative regulation of the immune response to tumor cells. Tumor cells are reported to suppress the host's immune response and escape from its immunological attack through activation of PD-1. BMS-936558/ONO-4538 is expected to normalize the host's immune response by blocking the binding of tumor cells to PD-1 thus potentially allowing the immune system to work against the tumor cells. In the U.S., BMS-936558/ONO-4538 is in Phase I and Phase II development across a variety of tumor types and treatment settings, including renal cell carcinoma and melanoma. In Japan, a Phase II clinical study for melanoma is under preparation by Ono.

About ORENCIA in Japan
Rheumatoid arthritis is an autoimmune disease characterized by inflammation of the joints as a result of the over-expression of pro-inflammatory cytokines. ORENCIA is a biologic therapy that works by inhibiting T-cell activation and suppressing the production of pro-inflammatory cytokines, which leads to the amelioration of the inflammation in joints of patients.

ORENCIA IV is available in more than 50 counties, and was launched in September 2010 in Japan where it is indicated for use in patients of rheumatoid arthritis for whom other therapies have failed.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

ORENCIA is a registered trademark of Bristol-Myers Squibb.

About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd. is a R&D-oriented pharmaceutical company specializing in creating innovative medicines in specific areas and is headquartered in Osaka, Japan.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]